Compare Amphastar Pharmaceuticals Inc (AMPH) vs British American Tobacco PLC (BTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs British American Tobacco PLC — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while British American Tobacco PLC trades at $58.96 (market cap $127.15B). The key difference: British American Tobacco PLC is far larger — about 153.9× Amphastar Pharmaceuticals Inc's market cap, and British American Tobacco PLC pays a 5.56% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BTI | |
|---|---|---|
Market Cap | $826.08M | $127.15B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $66.70 |
52-Week Low | $16.87 | $50.39 |
Enterprise Value | $1.22B | $168.38B |
Dividend Yield | — | 5.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
British American Tobacco (BTI) trades at $60.02, down 1.4% on the day, with a bearish technical signal from moving averages. The company shows strong profitability with a net income margin of 30.32% and a P/E ratio of 13.02, indicating potential undervaluation. Recent earnings have mostly beaten expectations, and the firm maintains a robust dividend, with two $0.83 payouts scheduled for H2 2026. However, 2023 saw a significant net loss, and 2025 cash flow is projected negative, highlighting volatility.
BTI offers a compelling value proposition with high margins and analyst support (66.7% buy ratings), but faces headwinds from regulatory pressures, declining cigarette volumes, and restructuring costs. The stock's outlook balances income appeal against sector-specific risks, requiring careful monitoring of its transition to smoke-free products and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →
